Remove 2020 Remove FDA Remove HIV Treatment and Prevention Agents
article thumbnail

Five Things For Pharmacists To Know About The Treatment Of Mycobacterium Tuberculosis

IDStewardship

AI-Generated Summary This article by infectious diseases pharmacist Aneeka Chavda outlines five key considerations for pharmacists in the treatment of Mycobacterium tuberculosis (TB), particularly drug-sensitive cases. The piece advocates for therapeutic drug monitoring (TDM) in specific high-risk groups to personalize treatment.

article thumbnail

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

pharmaphorum

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. On average, launches of 2020’s cohorts both underperformed. The scope of the problem. Launches, therefore, were happening.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Agile, Data-Driven Life Cycle Management for Continuous Manufacturing

ISPE

1 , 4 A Retrospective Journey In 2015, Vertex’s Orkambi was the first approved drug produced under a CM process for the treatment of cystic fibrosis. Table 1: List of FDA-approved commercial products using CM elements. Table 1: List of FDA-approved commercial products using CM elements. This is demonstrated by the rise from $1.05

article thumbnail

Ivermectin: A therapeutic approach to reduce high-risk cases of COVID

Druggist

Additionally, this drug is also known as anti-parasite successful against all viruses like HIV, Dengue, Influenza , and Zika virus. And stated its judicial use in preventing corona infection. To manage such a future crisis, healthcare experts might consider using Ivermectin tablets for its treatment and prevention.

article thumbnail

Oral COVID Agents

Pharmacy Friday Pearls

18 years Administration Oral Oral Oral PK/PD MOA: Nirmatrelvir – inhibitor of the SARS-CoV-2 main protease Prevents viral replicationRitonavir is a CYP3A inhibitor included to increase nirmatrelvir plasma levelsRitonavir alone has NO activity against SARS-CoV-2 Time to peak: Nirmatrelvir: 3 hrs & Ritonavir: 3.98 Introduction.

article thumbnail

How Balancing Iron Levels Can Help Your Thyroid

The Thyroid Pharmacist

And as we’ve seen, even with supplementation, you need to address your root causes to prevent iron supply and demand challenges. A 2020 study found that 28 percent of female marathon runners had iron deficiency, compared to only 1.6 Patients on hemodialysis may be prescribed IV or subcutaneous ESAs during dialysis treatments.

article thumbnail

Nine for 2022: International issues that are compelling, new or changed in 2022

pharmaphorum

The year 2020 ended on a note of hope, with the 8th December vaccination of 91-year-old Margaret Keenan, the world’s first person to receive a COVID-19 vaccine outside clinical trials. The next phase of the Covid-19 – from vaccines to treatments. New COVID-19 treatments will also be available in 2022, but they are not a panacea.